Source:http://linkedlifedata.com/resource/pubmed/id/15798847
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2005-3-30
|
| pubmed:abstractText |
At present, HIV testing and counselling during pregnancy represent the key entry point for women to learn their serostatus and for them to access, if they are HIV-positive, specific interventions to reduce mother-to-child transmission (MTCT) of HIV. However, the provision and uptake of testing and counselling services are inadequate, and many pregnant women in countries most affected by the HIV/AIDS epidemic remain unaware of their HIV status. The offer of single-dose nevirapine prophylaxis to women whose HIV status is unknown at the time of delivery has been proposed to circumvent these problems in high-prevalence settings. The potential advantages and disadvantages of three different programme approaches are considered: targeted programmes in which antiretroviral drugs are offered only to women who are known to be HIV-positive; combined programmes in which nevirapine prophylaxis is offered to women whose serostatus remains unknown at the time of delivery despite targeted programme inputs; and universal nevirapine prophylaxis programmes in which HIV testing and counselling are not available and all pregnant women, regardless of their serostatus, are offered nevirapine prophylaxis.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0042-9686
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
83
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
224-8
|
| pubmed:dateRevised |
2009-5-29
|
| pubmed:meshHeading |
pubmed-meshheading:15798847-Anti-HIV Agents,
pubmed-meshheading:15798847-Female,
pubmed-meshheading:15798847-HIV Infections,
pubmed-meshheading:15798847-HIV Seropositivity,
pubmed-meshheading:15798847-Health Status,
pubmed-meshheading:15798847-Humans,
pubmed-meshheading:15798847-Infectious Disease Transmission, Vertical,
pubmed-meshheading:15798847-Nevirapine,
pubmed-meshheading:15798847-Pregnancy,
pubmed-meshheading:15798847-Program Development,
pubmed-meshheading:15798847-Risk Assessment
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
|
| pubmed:affiliation |
Department of HIV/AIDS, World Health Organization, Geneva, Switzerland. sintt@who.int
|
| pubmed:publicationType |
Journal Article
|